According to the role of nAChRs in lung cancer cell development and drug resistance, the use of nAChR antagonists could block, or at least attenuate, the effect of nicotine (and other agonists, e.g., acetylcholine), thereby improving the efficacy of current chemotherapy agents such as cisplatin in combating cancer resistance. The gene discussed is CHRNA4; the disease is lung carcinoma.